Loading BCONZ...
PIA · Provider Intelligence Agent
Clinical trial site selection and data partner identification
Choosing the right sites and data partners decides whether a study recruits and whether a dataset can be assembled. PIA — BCONZ's Provider Intelligence Agent — turns a research requirement into a universe of candidate hospitals, research sites and provider networks, built from public trial, publication and provider evidence.
Each candidate is ranked with stated rationale and visible evidence. Where public evidence cannot establish something — such as the number of eligible patients — PIA reports it as unknown rather than estimating it.
Clinical trial site selection criteria, evidenced
Common site selection criteria for clinical trials include experience in the indication, an active research programme, access to the right patient population and the ability to support data sharing. PIA evidences each from public sources so the shortlist can be defended:
- Prior and current trials in the indication, from trial registries
- Published research output in the disease area
- Country and market footprint
- An explicit evidence state for every score, including where evidence is absent
Clinical trial feasibility assessment
A feasibility assessment asks whether a study can be run where it is planned. PIA supports the site and partner side of that question — which providers are credible candidates, and why — so feasibility conversations start from evidence rather than a list of names.
Patient cohort identification through the right partners
Identifying a patient cohort starts with identifying the organisations that hold it. PIA shortlists the providers; HARM can then assess what each partner's data can actually support.
Frequently asked questions
PIA: common questions
What is clinical trial site selection?
It is the process of choosing the hospitals and research sites that will run a study, based on criteria such as experience in the indication, patient access and operational capacity.
Does PIA estimate how many eligible patients a site has?
No. Public evidence rarely supports a reliable count, so PIA reports it as unknown. Patient numbers come from the partner's own data, for example through a HARM readiness assessment.
Which markets does PIA cover?
PIA builds its provider universe from international public trial and publication evidence, with country filters for the markets a study targets.
Related capabilities
HARM · Healthcare data readiness assessment
A healthcare data readiness assessment that runs inside your own systems and shows what your data can support for research and AI — without the data leaving.
DIA · Demand Intelligence Agent
Responsible healthcare data monetization starts with demand: DIA shows who has published a need for data like yours, and which of their needs your dataset meets.
See PIA on your own question or dataset.